Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

replay ID # 371588. The conference call will be broadcast live over the Internet at www.halozyme.com and the replay will be available on the company's Web site for seven days.

About Halozyme TherapeuticsHalozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche and with Baxter to apply Enhanze technology to biological therapeutics including Herceptin®, MabThera® and immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing and scope of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statemen
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
4. Halozyme Receives $5.5 Million Payment From Baxter
5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that executives from ... the month of September.  , ... Rodman & Renshaw,s 17th Annual Global Investment Conference on ... the St. Regis Hotel in New York ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... weighing needs and expertly narrows down the product choices to a manageable shortlist ... pares down the list to models that fit best with the customer’s industry ...
(Date:8/26/2015)... N.J. , Aug. 26, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... CEO will present at the Sidoti & Company Emerging ... conference will be held at the New York Marriott ... presentation will be available through the investor relations section ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2
... Milwaukee Brookfield-based Fiserv Inc. has unveiled ... company's positions in financial processing and health-plan administration. ... Congress in 2004, healthcare banking is a set ... for consumers and moving payments between parties in ...
... business struggles with the problems of clinical risks and litigation, ... the use of war-game exercises, in which scenarios that could ... be simulated in the course of hours and allow for ... can pose a real threat. , ,While simulations have been ...
... Corporation and Middleton-based Bone Care International Inc. announced ... their proposed merger. , ,Genzyme and Bone Care have signed ... Care in an all-cash transaction valued at $33.00 per ... by Bone Care's shareholders at a meeting on ...
Cached Biology Technology:Medical simulations identify potential problems before they can pose a real threat 2Medical simulations identify potential problems before they can pose a real threat 3
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... SALT LAKE CITY, July 12, 2010 Shifty eyes ... the truth. Now a group of University of Utah researchers ... Educational psychologists John Kircher, Doug Hacker, Anne Cook, Dan ... a promising alternative to the polygraph for lie detection. The ...
... critical U.S. crop expected to help feed livestock and people ... production of clean energy, plant breeders are continually seeking ways ... role corn roots play in this regard, an agricultural engineer ... Urbana-Champaign have teamed up to examine corn root complexity and ...
... Letters , recently published an article highlighting the ... professor in the Mechanical Engineering Department at Stevens ... V Nanogenerator for Mechanical Energy Harvesting Using PZT ... energy harvesting technologies that could potentially power wireless ...
Cached Biology News:'You can't hide your lyin' eyes' 2'You can't hide your lyin' eyes' 3What secrets are stored in the roots of corn plants? 2What secrets are stored in the roots of corn plants? 3Nano Letters publishes Dr. Yong Shi's energy harvesting technology 2
... are ideal for storage and transport of ... racks withstand extreme temperatures, making them an ... also be autoclaved for use in sterile ... accommodates 0.5ml microcentrifuge tubes, the other 1.5ml ...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
... of universal lysis buffer, PCR mix, DNA ... 25 l volume PCR reactions. This system ... or positive rod and coccus bacteria, such ... Staphylococcus Aureus, Streptococcus Agalactiae, and etc. With ...
...
Biology Products: